Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

Mild traumatic brain injury (mTBI), a significant public health concern, is diagnosed by clinical assessment and computed tomography (CT) scans, while glial fibrillary acidic protein (GFAP) and ...

Researchers from Vrise Therapeutics Inc. and Vegen Therapeutics Pvt Ltd. presented preclinical data for VRTX-531, an allosteric inhibitor of ubiquitin carboxyl-terminal hydrolase 1 (USP1), being ...